Rheumatology

Updated "User's Guide" Published for Anti-TNFs in IBD

August 27th 2020

By Deana Ferreri, PhD

Two decades of using anti–tumor necrosis factor (TNF) drugs in inflammatory bowel disease (IBD) have answered some questions and left others unanswered.

Mylan, Lupin Launch Etanercept Biosimilar in Germany

August 27th 2020

By Skylar Jeremias

Article

The launch marks the first European market entry for Nepexto.

Symposium: Treating Inflammatory Conditions With Biosimilars

August 26th 2020

By The Center for Biosimilars

Article

A September 29, 2020, symposium with Sonia T. Oskouei, PharmD, BCMAS, DPLA, of Cardinal Health will explore how to incorporate biosimilars into the treatment of inflammatory conditions.

British Columbia Moves Into Third Phase of Mandatory Switching

August 25th 2020

By Tony Hagen

Article

The statistics show that for the Rocky Mountain province, biosimilar savings are pouring into the health care system and allowing for significantly greater access.

Biogen: Anti-TNF Biosimilars Are Underutilized

August 25th 2020

By Tony Hagen

Article

Two Biogen officials make the case for getting anti–tumor necrosis factor (TNF) biosimilars into wider play.

Celltrion, Intract Pharma Strive for World's First Oral Infliximab

August 22nd 2020

By Tony Hagen

Article

Intract Pharma believes infliximab can be delivered orally and, in conjunction with Celltrion Group, aims to apply its technology and expertise to make it happen.

For Employers, Rheumatoid Arthritis Cost Overshadows Incidence

August 18th 2020

By Skylar Jeremias

Article

Employers could save thousands of dollars by promoting the use of biosimilars that will keep employees with rheumatoid arthritis from having to file for disability, according to Brian Gifford, PhD, research director of the Integrated Benefits Institute.

ACCC's McBride on the Need for Biosimilar Education

August 18th 2020

By The Center for Biosimilars

Article

Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.

Winegarden: Biosimilars Market Lacks Oomph

August 17th 2020

By Tony Hagen

Article

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Biosimilars Gain Market Share and Advocates Get Aboard

August 15th 2020

By Skylar Jeremias

Article

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.